Background and Objectives: Sepsis is a critical condition with high mortality rates worldwide. The early identification of patients at an elevated risk of mortality remains a significant clinical challenge. The lactate/albumin (L/A) ratio has emerged as a potential prognostic biomarker in critically ill patients. This exploratory study aimed to evaluate the L/A ratio as a predictor of mortality in patients with sepsis or septic shock and to describe the demographic and clinical characteristics of affected patients in a tertiary referral hospital in Western Mexico. Materials and Methods: A retrospective cross-sectional study was conducted including patients diagnosed with sepsis or septic shock between January 2022 and June 2023. Clinical and biochemical data, including serum lactate and albumin levels, were collected from medical records to calculate the L/A ratio. The primary outcome was in-hospital mortality. The statistical analysis included receiver operating characteristic (ROC) curves to evaluate the L/A ratio’s discriminative capacity, a bivariate analysis, and a multivariate logistic regression to identify independent risk factors for mortality. Results: A total of 141 patients were included in the study, and the median L/A ratio was significantly higher in non-survivors compared to survivors (0.95 vs. 0.60, p = 0.003). The ROC analysis showed an area under the curve (AUC) of 0.651, with a sensitivity of 36.5% and specificity of 82% at a cutoff value of 1.12. The multivariate analysis identified serum albumin levels and vasopressor use as independent predictors of mortality. Conclusions: The L/A ratio demonstrates potential as a simple and accessible prognostic biomarker for mortality in sepsis, though its utility requires further validation in larger prospective studies.
The objective of the study was to describe the frequency of acute myocardial injury (AMI) assessed by high-sensitivity cardiac troponin I (hs-cTnI) levels and to determine the possible initial risk factors (related to the characteristics of the patient, the disease, and the initial management) in a population of adult patients with early sepsis (within the first 72 h of diagnosis) in a single tertiary hospital center in western Mexico. For the inferential statistics, the proportions of the categorical dichotomous variables were compared using the chi-square test. In all analyses, p values less than 0.05 with a 95% confidence interval were considered significant. We included a total of 64 patients diagnosed with early sepsis, of whom 46 presented elevated hs-cTnI and were classified as having AMI. In our study, the frequency of AMI in patients with early sepsis was 71.87%, and no significant differences were found in all of the characteristics of patients with early sepsis with and without AMI, nor was any significant association found with any of the variables analyzed. In the population of western Mexico, the frequency of AMI in patients with early sepsis, assessed by hs-cTnI levels, is high and similar to that reported in other populations worldwide.
Intestinal failure (IF) is a debilitating condition characterized by the insufficient function of the gastrointestinal tract to absorb nutrients and fluids essential for life. This review consolidates recent advancements and challenges in managing IF among adult and pediatric populations, highlighting differences in etiology, management, and outcomes. Over the recent years, significant strides have been made in the nutritional and medical management of IF, significantly reducing mortality rates and improving the quality of life for patients. Key advancements include the development and availability of glucagon-like peptide-2 (GLP-2) analogs, improved formulations of parenteral nutrition, and the establishment of specialized interdisciplinary centers. Short bowel syndrome (SBS) remains the predominant cause of IF globally. The pediatric segment is increasingly surviving into adulthood, presenting unique long-term management challenges that differ from adult-onset IF. These include the need for tailored nutritional support, management of IF-associated liver disease, and addressing growth and neurodevelopmental outcomes. The therapeutic landscape for IF continues to evolve with the development of new treatment modalities and better understanding of the condition’s pathophysiology. However, disparities in treatment outcomes between children and adults suggest the need for age-specific management strategies. This review underscores the importance of a nuanced approach to IF, incorporating advancements in medical science with a deep understanding of the distinct needs.
Background/Objectives: Avoidable mortality—deaths before age 75 from preventable or treatable causes—is a key indicator of health system performance. In Mexico, nearly two-thirds of municipalities lack hospital beds, yet no study has examined the municipal-level association between healthcare infrastructure and avoidable mortality. This study assessed whether healthcare desert status is independently associated with avoidable mortality after adjusting for social deprivation. Methods: This ecological study analyzed 1891 Mexican municipalities (population ≥ 1000) over 2015–2024. Avoidable deaths were classified per OECD/Eurostat criteria (January 2022 revision). Healthcare desert status was defined by municipal hospital bed availability from 2019 facility data. Negative binomial mixed-effects regression estimated incidence-rate ratios (IRRs) adjusted for social deprivation, age structure, and state-level heterogeneity. Interrupted time-series analysis quantified pandemic disruption. Results: Of 4,960,244 deaths under 75 years, 81.2% were avoidable. Of 1891 municipalities, 1187 (62.8%) lacked hospital beds (healthcare deserts). Desert municipalities had 42.5% higher avoidable mortality (IRR = 1.425; 95% CI: 1.370–1.482; pre-pandemic 2015–2019), which attenuated to 1.353 after age-structure adjustment. Each standard-deviation increase in hospital beds (1 SD ≈ 2.2 beds per 1000) was associated with 7.9% lower mortality (IRR = 0.921). Avoidable mortality exhibited strong spatial clustering (Moran’s I = 0.382) in southern Mexico. By 2024, the desert–adequate mortality gap had widened by approximately five fold (from 12 to 69 per 100,000 population). Conclusions: Healthcare deserts are independently associated with substantially higher avoidable mortality in Mexico. The COVID-19 pandemic durably amplified pre-existing disparities associated with healthcare infrastructure deficits. Targeted hospital expansion in underserved municipalities is urgently needed, alongside investment in social determinants of health.
Background/Objectives: Escherichia coli is the predominant pathogen in community-onset urinary tract infections (UTIs) requiring hospitalization. This study characterized antimicrobial resistance profiles, biofilm formation, extended-spectrum β-lactamase (ESBL) gene distribution, and phylogenetic background of E. coli isolates from hospitalized UTI patients in Western Mexico. Methods: Seventy isolates (September 2023–September 2024) underwent susceptibility testing (CLSI M100, 35th edition), multiplex PCR for blaTEM, blaCTX-M, and blaSHV genes, crystal violet biofilm quantification, and Clermont quadruplex PCR phylotyping. Associations were evaluated by Fisher’s exact test with Benjamini–Hochberg FDR (BH-FDR) correction. Results: ESBL phenotype and MDR were detected in 57.1% and 58.6% of isolates. After BH-FDR correction, ESBL production was significantly associated with amikacin (OR = 5.55; 95% CI: 1.80–18.74; q = 0.002) and TMP-SMX non-susceptibility (OR = 3.00; 95% CI: 1.02–9.23; q = 0.036); ciprofloxacin non-susceptibility was linked to MDR status (OR = 7.21; 95% CI: 1.28–75.66; q = 0.017) but not ESBL phenotype. Biofilm was detected in 77.1% of isolates. blaTEM predominated among ESBL producers (85.0%). Phylogroup B2 (51.4%) was inversely associated with recurrent UTI on both univariate (OR = 0.17; 95% CI: 0.03–0.73; p = 0.008) and adjusted analysis (adjusted OR = 0.19; 95% CI: 0.05–0.81; p = 0.025). Phylogroup C (22.9%) exhibited the highest MDR prevalence (81.3%) and the highest biofilm formation rate among phylogroups (87.5%). Conclusions: The high prevalence of ESBL-producing and MDR E. coli, combined with an unexpected predominance of blaTEM, reveals a distinctive local resistance landscape diverging from regional trends. The inverse association of phylogroup B2 with recurrence and TMP-SMX resistance reinforces the clinical value of phylogenetic surveillance in guiding UTI management strategies.
4 August 2026 in Therapeutic Advances in Infectious Disease
Background: Pneumocystis jirovecii pneumonia (PJP) in non-HIV immunocompromised adults carries 30%–60% mortality. Adjunctive corticosteroids are standard in HIV-PJP but remain contested in non-HIV PJP. Objectives: To determine whether adjunctive corticosteroids reduce mortality and invasive mechanical ventilation (IMV) in non-HIV PJP, and whether effect estimates differ between randomized and observational study designs. Design: Systematic review and meta-analysis. Data sources and methods: Six databases and two trial registers were searched from inception to February 7, 2026. Randomized and observational studies comparing adjunctive corticosteroids versus no corticosteroids or placebo in non-HIV adults with PJP were eligible. Random-effects meta-analyses (restricted maximum likelihood) of two co-primary outcomes included subgroup, sensitivity, E -value, and Grading of Recommendations Assessment analyses. Results: Twenty-eight studies were included (one randomized controlled trial (RCT), 27 observational; 5300 patients): 22 contributed corticosteroid-versus-no-corticosteroid comparisons and six contributed dose-comparison data only. Evidence was discordant by design (interaction ): the RCT showed lower IMV (hazard ratio (HR) 0.36, 95% CI 0.14–0.90) and lower 90-day mortality (HR 0.59, 0.37–0.93); regression-adjusted observational studies suggested harm (odds ratio (OR) 1.56, 1.10–2.22); propensity-based estimates were null-compatible. Pre-specified mortality pools were non-significant short-term (OR 1.22, 0.88–1.70) and intermediate-term (OR 1.39, 0.85–2.29). Secondary infections ( ): OR 1.04 (0.63–1.72); RCT 0.59 (0.32–1.06). E -values for RCT effects (3.44 IMV; 2.24 mortality) exceeded the 1.81 E -value of the adjusted observational mortality pool. Certainty was very low for pooled mortality and moderate for RCT outcomes. Conclusion: Reliable inference rests on the single RCT rather than the pooled observational estimate, which is discordant by design and most consistent with confounding by indication. In the RCT, corticosteroids did not significantly reduce 28-day mortality but lowered IMV and 90-day mortality and sped respiratory recovery, without clear excess secondary infections (low certainty). Corticosteroids may be considered for severe respiratory failure using the PIC (ClinicalTrials.gov NCT02944045) protocol; adequately powered confirmatory trials are needed. Trial registration
:
PROSPERO CRD420261304396.